"Spill" the tea! Mental health startups and others.
Berlin pet care startup felmo raises Series A funding
Six months after raising a seed financing, felmo, a Berlin-based pet health brand, announced it has raised a Series A round of “several million euros”. Redalpine led the investment, with previous backers HV Capital and 468 Capital tagging along.
Founded in 2019, the German company offers a combination of at-home veterinary and digital services, in an effort to make pet care easier for the animals, their owners and veterinarians alike. In addition to booking an appointment, the felmo app offers features such as a chat with a veterinarian, health checks, digital records and other pet care guidance.
The fresh capital will be used to expand into new regions, add more services and scale the team to make all that possible.
Berlin pet care startup felmo raises Series A funding - Tech.eu
Six months after raising a seed financing, felmo, a Berlin-based pet health brand, announced it…
NewAmsterdam Pharma Closes $196M Series A Funding
NewAmsterdam Pharma (NAP), a Naarden, the Netherlands-based clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, closed a $196M (€160M) Series A funding round.
Led by Michael Davidson, MD, chief executive officer, and John Kastelein, MD, PhD, FESC, chief scientific officer, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases.
The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor, is being developed for patients who are not well-controlled on statins.
NewAmsterdam Pharma Closes $196M Series A Funding
NewAmsterdam Pharma (NAP), a Naarden, the Netherlands-based clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, closed a $196M (€160M) Series A funding round
IO Biotech Completes €127M Series B Financing
IO Biotech, a Copenhagen, Denmark-based clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, raised €127m in Series B financing.
The round was led by HBM Healthcare Investments, and other new investors joining the round.
The company intends to use the net proceeds of the transaction towards the funding of clinical trials for its early and late-stage immuno-oncology programs, including a large randomized trial for IO102 and IO103 with anti-PD-1 monoclonal antibodies in metastatic melanoma.
IO Biotech Completes €127M Series B Financing - FinSMEs
IO Biotech, a Copenhagen, Denmark-based clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, raised €127m in Series B financing
Immunocore Closes $75M Series C Funding Round
Immunocore, a Milton Park, Oxfordshire, U.K.-based late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, completed a $75.0m Series C private financing round.
Led by an existing investor, the Series C financing included support from existing investors and funds and accounts managed by BlackRock.
The proceeds will enable Immunocore to further expand and accelerate its growing clinical stage pipeline of ImmTAX™ (Immune mobilising monoclonal TCRs Against Cancer, Infectious Diseases and Autoimmune) molecules, including its lead program tebentafusp (IMCgp100).
Immunocore Closes $75M Series C Funding Round - FinSMEs
Immunocore, a UK and US-based late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, completed a $75.0m Series C private financing round
London’s mental health startup Spill raises €2.25M to create more psychologically considerate workplace; here’s how
In a recent move, Spill raised £2M (nearly €2.25M) funding from Ada Ventures along with Seedcamp and the government’s Future Fund initiative. Also, Francesca Warner, partner at Ada Ventures joins the Spill board.
Addressing the mental health wellbeing of employees who are remotely working is a London-based mental health startup called Spill. It offers remote mental health support for companies via Slack, a well-known workplace messaging tool.
The fresh fund will be used to develop proactive tools that will help the company create a more psychologically considerate workplace. It will also focus on the prevention of mental health issues instead of treatment. This funding round follows the nearly €750K investment it secured from Passion Capital back in 2019.
London’s mental health startup Spill raises €2.25M to create more psychologically considerate workplace; here’s how
London’s mental health startup Spill raises €2.25M to create more psychologically considerate workplace.
Dublin’s Frankie Health gets $1.5 million to develop mental health platform for employees
Frankie Health, a new mental health tech startup out of Dublin, has raised $1.25 million to develop the platform and grow the team. E15 VC, an investment firm based in Hong Kong, contributed the whole round, plus a previous $250,000.
Founded in August 2020, the B2B platform helps employers connect their teams with therapists and other online guidance about wellness. For example, teams can commit to a meditation practice together and track it digitally. The startup says machine learning keeps everything personalised and effective, while end-to-end encryption keeps everything private.
Over the next year, the startup will create and fill 20 new jobs across engineering, design and marketing. Frankie Health’s Series A round is slated for 2022.
Dublin's Frankie Health gets $1.5 million to develop mental health platform for employees - Tech.eu
Frankie Health, a new mental health tech…
Tessera Therapeutics Raises Over $230M in Series B Financing
Tessera Therapeutics, a Cambridge, Mass.-based early-stage life sciences company founded by Flagship Pioneering, raised over $230M in Series B financing.
The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2, with participation from Qatar Investment Authority (QIA) and others.
Led by Geoffrey von Maltzahn, CEO and Co-Founder. and Noubar Afeyan, Chairman and Co-Founder, Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source with applications in cardiovascular, oncological, neurodegenerative, and infectious diseases.
The company intends to use the funds to accelerate research and development in its Gene Writing technologies, expand its team, and establish manufacturing and automation capabilities critical for its platform and programs.
